SFXN1 and age-related macular degeneration: Several groups have used plasma complement proteins as biomarkers in AMD for early detection, disease monitoring or to guide intervention; elevated plasma levels of activation fragments C3a, C3dg, C5a, and Bb, terminal complement complex (TCC), and fD are potential AMD biomarkers and can similarly be used to anticipate aHUS recurrences [31–33].